BR112014023642A2 - proteína interferon-lambda4 (ifnl4), moléculas de anticorpo relacionadas, e usos das mesmas - Google Patents

proteína interferon-lambda4 (ifnl4), moléculas de anticorpo relacionadas, e usos das mesmas

Info

Publication number
BR112014023642A2
BR112014023642A2 BR112014023642A BR112014023642A BR112014023642A2 BR 112014023642 A2 BR112014023642 A2 BR 112014023642A2 BR 112014023642 A BR112014023642 A BR 112014023642A BR 112014023642 A BR112014023642 A BR 112014023642A BR 112014023642 A2 BR112014023642 A2 BR 112014023642A2
Authority
BR
Brazil
Prior art keywords
interferon
protein
lambda4
antibody molecules
ifnl4
Prior art date
Application number
BR112014023642A
Other languages
English (en)
Inventor
Muchmore Brian
Prokunina Liudmila
A Porter-Gill Patricia
P Donnelly Raymond
R O'brien Thomas
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of BR112014023642A2 publication Critical patent/BR112014023642A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

resumo patente de invenção: "proteína interferon-lambda4 (ifnl4), moléculas de anticorpo relacionadas, e usos das mesmas". a invenção refere-se à identificação de uma proteína análoga a interferon (ifnl4) e a sua associação genética com a eliminação espontânea de uma infecção por hcv e resposta ao tratamento para infecção por hcv.
BR112014023642A 2012-03-28 2013-03-14 proteína interferon-lambda4 (ifnl4), moléculas de anticorpo relacionadas, e usos das mesmas BR112014023642A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261616664P 2012-03-28 2012-03-28
PCT/US2013/031624 WO2013148272A1 (en) 2012-03-28 2013-03-14 A NOVEL INTERFERON-λ4 (IFNL4) PROTEIN, RELATED NUCLEIC ACID MOLECULES, AND USES THEREOF

Publications (1)

Publication Number Publication Date
BR112014023642A2 true BR112014023642A2 (pt) 2017-07-18

Family

ID=47998550

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023642A BR112014023642A2 (pt) 2012-03-28 2013-03-14 proteína interferon-lambda4 (ifnl4), moléculas de anticorpo relacionadas, e usos das mesmas

Country Status (8)

Country Link
US (3) US9678074B2 (pt)
EP (1) EP2831106B1 (pt)
JP (1) JP6120944B2 (pt)
CN (1) CN104540849B (pt)
AU (1) AU2013240301B2 (pt)
BR (1) BR112014023642A2 (pt)
CA (1) CA2869899C (pt)
WO (1) WO2013148272A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013240301B2 (en) 2012-03-28 2017-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A novel interferon-lambda4 (IFNL4) protein, related nucleic acid molecules, and uses thereof
CN106222178A (zh) * 2016-08-08 2016-12-14 武汉大学 一种重组干扰素λ4编码cDNA序列及其制备方法和应用
JP6948685B2 (ja) * 2016-11-04 2021-10-13 国立大学法人金沢大学 抗癌作用増強剤及び癌治療支援方法
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods
CN107893087A (zh) * 2017-11-07 2018-04-10 北京康宝利华生物科技有限公司 一种重组猪λ3干扰素的制备方法及其应用
CA3190062A1 (en) * 2019-01-17 2020-07-23 University Health Network Tissue phantoms
US20230070752A1 (en) * 2019-08-21 2023-03-09 Korea Advanced Institute Of Science And Technology Novel interferon lambda variant and method of producing the same
US20240009292A1 (en) * 2020-10-01 2024-01-11 The Johns Hopkins University Bcg based vaccine compositions and methods of use thereof
CN114920817B (zh) * 2022-05-12 2023-09-05 华中农业大学 一种猪干扰素λ4重组蛋白及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0648334A4 (en) 1992-07-02 1996-11-20 Quidel Corp IMMUNOASSAY USING DYE-COMPLEXED ENZYME CONJUGATES.
US5424193A (en) 1993-02-25 1995-06-13 Quidel Corporation Assays employing dyed microorganism labels
WO1994029696A1 (en) 1993-06-09 1994-12-22 Quidel Corporation Antigen-specific one-step assays
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5656502A (en) 1995-06-07 1997-08-12 Diagnostic Chemicals Limited Test strip holder and method of use
US6001658A (en) 1996-09-13 1999-12-14 Diagnostic Chemicals Limited Test strip apparatus and method for determining presence of analyte in a fluid sample
GB9817266D0 (en) 1998-08-07 1998-10-07 Imperial College Method
ATE385517T1 (de) * 1999-12-08 2008-02-15 Amgen Inc Interferon ähnliche moleküle, und deren verwendungen
CA2735439A1 (en) * 2008-08-28 2010-03-04 Vertex Pharmaceuticals Incorporated Analysis of hcv genotypes
US8535887B2 (en) 2009-05-21 2013-09-17 Merck Sharp & Dohme Corp. Genetic markers associated with interferon-alpha response
US20100316608A1 (en) 2009-06-15 2010-12-16 Vijayaprakash Suppiah Method of Determining A Response To Treatment With Immunomodulatory Composition
CN102665753A (zh) 2009-07-31 2012-09-12 佛多斯大学医学研究中心 诊断或预测hcv感染的患者中丙型肝炎后果的方法
RU2567806C2 (ru) 2009-12-22 2015-11-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Усиление прогностической ценности полиморфизма гена il28b в комбинации с количественной оценкой ip-10 в сыворотке при ответе на пегинторферон и рибавирин по сравнению с каждым из этих биомаркеров в отдельности
US20140154209A1 (en) 2011-06-30 2014-06-05 Centre Hospitalier Universitaire Vaudois Polymorphisms associated with non-response to a hepatitis c treatment or susceptibility to non-spontaneous hepatitis c clearance
US20140271542A1 (en) 2011-10-05 2014-09-18 The United States Of America As Represented By The Secretary, Department Of Health And Human Service Genetic marker for predicting prognosis in patients infected with hepatitis c virus
AU2013240301B2 (en) 2012-03-28 2017-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A novel interferon-lambda4 (IFNL4) protein, related nucleic acid molecules, and uses thereof

Also Published As

Publication number Publication date
CN104540849A (zh) 2015-04-22
US9678074B2 (en) 2017-06-13
CA2869899A1 (en) 2013-10-03
WO2013148272A1 (en) 2013-10-03
CA2869899C (en) 2021-06-22
AU2013240301B2 (en) 2017-10-05
US20200292546A1 (en) 2020-09-17
AU2013240301A1 (en) 2014-11-06
US20150050640A1 (en) 2015-02-19
CN104540849B (zh) 2020-07-28
EP2831106A1 (en) 2015-02-04
JP2015514709A (ja) 2015-05-21
US10962539B2 (en) 2021-03-30
EP2831106B1 (en) 2020-07-15
JP6120944B2 (ja) 2017-04-26
US20170254808A1 (en) 2017-09-07
WO2013148272A9 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
BR112014023642A2 (pt) proteína interferon-lambda4 (ifnl4), moléculas de anticorpo relacionadas, e usos das mesmas
BR112014007069A2 (pt) proteínas de fusão para o tratamento de distúrbios metabólicos
BR112018010084A2 (pt) ligantes de pd1 e/ou lag3
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA201890006A1 (ru) Применение экзосом для лечения болезни
BR112014018210A2 (pt) moléculas de ácido nucleico artificiais para expressão de proteína ou peptídeo melhorada
WO2017040930A3 (en) Biomarkers predictive of cytokine release syndrome
BR112019005587A2 (pt) proteínas de ligação recombinantes e sua utilização
EA201000424A1 (ru) Антитела к il-23
SG10201903381TA (en) Artificial nucleic acid molecules
BR112012027055A2 (pt) agente estabilizante para proteínas farmacêuticas.
BR112014023898A2 (pt) moléculas de ácido nucleico artificiais compreendendo 5''utr top
BR112014023800A2 (pt) moléculas de ácidos nucleicos artificiais
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
BR112015008708A2 (pt) composição para clivagem de dna alvo compreendendo um rna guia específico para o dna alvo e ácido nucleico que codifica proteína cas ou proteína cas e uso da mesma
BR112018011002A2 (pt) variantes de fgf21
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
DK3233129T3 (da) Nukleinsyrekonstrukter og genterapivektorer til anvendelse i behandlingen af wilsons sygdom og andre lidelser
CY1124667T1 (el) Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα
BR112015030229A2 (pt) Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado
BR112015006731A2 (pt) combinações e usos das mesmas
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
BR112014010806A2 (pt) ligadores à base de tirosina para a ligação reversível de peptídeos
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.